Blocking Effect of a Monoclonal Antibody against Recombinant Pvs25 on Sporozoite Development in Anopheles sinensis

Sung-Ung Moon,1† Hyung-Hwan Kim,2,3† Tong-Soo Kim,4† Kyung-Mi Choi,1 Chang-Mi Oh,1 Yong-Joo Ahn,2 Seo-Kyoung Hwang,2 Youngjoo Sohn,2 E-Hyun Shin,6 Hyuck Kim,3 and Hyeong-Woo Lee1,7*

Division of Malaria and Parasitic Diseases, National Institute of Health, Centers for Disease Control and Prevention, Seoul 122-701, Republic of Korea; Vascular Medicine Research Unit, Brigham and Women’s Hospital/Harvard Medical School, Cambridge, Massachusetts 02139; International Research Center of Bioscience & Biotechnology, Jungwon University, Goesan 367-805, Republic of Korea; Department of Parasitology, College of Medicine, Inha University, Incheon 405-751, Republic of Korea; Department of Gynecology, College of Oriental Medicine, Sangji University, Wonju 220-717, Republic of Korea; Division of Medical Entomology, National Institute of Health, Centers for Disease Control and Prevention, Seoul 122-701, Republic of Korea; and Department of Pathology, University of Florida, J-566, 1600 SW Archer Road, Gainesville, Florida 32610

Received 15 March 2010/Returned for modification 5 April 2010/Accepted 28 May 2010

To develop a vaccine to block the transmission of vivax malaria, the gene encoding the ookinete surface protein Pvs25 was cloned from a Korean malaria patient. The Pvs25 gene was 660 bp long, encoding 219 amino acids. It was subcloned into the expression vector pQE30 and expressed in Escherichia coli. The expressed recombinant protein, named rPvs25, showed a molecular mass of approximately 25 kDa by SDS-PAGE analysis. An anti-rPvs25 monoclonal antibody produced in BALB/c mice was able to inhibit sporozoite development in the mosquito Anopheles sinensis, which is known as the malaria transmission vector in the Republic of Korea. In addition, rPvs25 produced a relatively high antibody titer in BALB/c mice that lasted for more than 6 months. Based on these results, we suggest that recombinant Pvs25 could be a useful antigen in the development of a vaccine to prevent local malaria transmission in the Republic of Korea.

Although Plasmodium vivax has presumably been prevalent in the Republic of Korea for several centuries, the incidence of vivax malaria has rapidly decreased as a result of a national malaria eradication program conducted by the Korean government in collaboration with the World Health Organization (WHO) (12, 13, 24). After a report of two malaria patients in 1985 (18), there were no further reported cases until 1993. Between 1993 and 2000, the number of malaria cases rapidly increased. Thus, starting in 2000, the Korean government made efforts to reduce the incidence of malaria, resulting in a decrease in reported malaria cases over the course of several years. Nevertheless, it is unlikely that malaria has been eradicated thoroughly from the Republic of Korea; treatment failure is reported for approximately 3 to 4% of cases every year (Korean Centers for Disease Control and Prevention, unpublished data), and there is a steady influx of travelers and workers from countries where malaria is prevalent. Malaria is caused by protozoan parasites of the genus Plasmodium, primarily Plasmodium falciparum and P. vivax, and is transmitted in nearly 100 countries, where approximately 2.0 billion people are exposed to infection. The WHO estimates that the global burden of malaria is approximately 500 million clinical cases per year, and recent estimates suggest that 70 to 80 million of those cases are due to P. vivax (24). Unfortunately, most trials for developing a malaria vaccine have not been successful because of the complicated life cycle of the malaria parasite. To overcome this problem, several researchers began to develop transmission-blocking vaccines (TBVs), which are designed to induce an immune response in the human host, inhibiting the formation of ookinetes or oocysts in the mosquito vector and thus preventing the spread of the parasites between humans. For example, in P. falciparum, monoclonal antibodies against the Pfs230 and Pfs48/45 proteins, which are expressed in the gametocytes/gametes, can block fertilization. In addition, monoclonal antibodies against the P25 and P21/28 surface protein family members, which are expressed in zygotes and ookinetes, can inhibit postfertilization events (2, 10). Proteins in the P25 and P21/28 families are distinctive, having four evolutionarily conserved tandem epidermal growth factor (EGF)-like domains attached to the parasite surface by a glycosylphosphatidylinositol (GPI) anchor. Pfs25 and Pfs28 of P. falciparum and Pfs28 of rodent malaria parasites have been cloned and are well characterized (5, 6, 20). In Plasmodium yoelii, antibodies against the P25 homolog Pys25 can inhibit zygote formation (22). In Plasmodium gallinaceum, polyclonal antibodies against Pgs28, the homolog of P21/28, inhibit the development of zygotes into ookinetees in vitro and the development of ookinetes into oocysts (4). In P. vivax, antibodies against Pvs25 and Pvs28, which were cloned from the Sall strain, have the ability to block parasite formation in infected mosquitoes (8). However, Pvs25 contains an antigenic polymorphism that causes problems with a Sall strain-based vaccine. Therefore, in this study, we report the cloning of the...
ookinete surface protein Pvs25 from a Korean isolate that could be a suitable antigen for the development of a transmission-blocking vaccine for use in South Korea. It would be time-consuming and laborious to immunize the more than 10 million individuals in areas of malaria endemicity in South Korea with precise immunization schedules. One way to circumvent the logistical difficulties would be to develop an edible malaria vaccine, so we also addressed whether immune responses could be evoked in vivo by the oral administration of the recombinant Pvs25 (rPvs25) protein.

**MATERIALS AND METHODS**

**Parasites.** For the artificial blood fed to the *Anopheles* vector mosquitoes, malaria blood samples were collected from patients infected with *P. vivax* who had never been abroad. The developmental stage of the parasite in each blood sample was determined by examination of thin blood films. Whole-blood samples were stored in the refrigerator (-4°C) or at room temperature until the mosquitoes were ready to feed. When the presence of gametocytes was confirmed, the parasitemia for each sample was calculated. The remaining blood samples were used for genomic DNA preparation. All samples were collected under human use protocols that were reviewed and approved by the Human Ethics Committee of the National Institute of Health of the Republic of Korea.

**PCR and cloning.** To amplify the ookinete surface protein gene (*Pvs25*), a specific primer set for *Pvs25* was designed based on the DNA sequences listed in GenBank (accession no. AF083502). The primers contained restriction sites that were used in expression and cloning experiments. rPvs25-F (5′-GGATCCACCTCTTACTTACGCGGC-3′) contained a BamHI site at the 5′ end, and rPvs25-R (5′-GTGATCCAGGCGGATGCG-3′) contained a KpnI site at the 5′ end. *P. vivax* genomic DNA was extracted from the whole blood of a malaria patient by use of a QiAamp blood kit (Qiagen Co., Hilden, Germany). PCR was performed with AccuPower PCR premix (Bioneer Co., Taeseon, South Korea), 50 ng of the purified genomic DNA, and 40 pmol (each) of the reverse and forward primers described above. The total volume was adjusted to 20 µl with distilled water. Cycling conditions were as follows: initial denaturation at 94°C for 5 min, followed by 35 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min and a final incubation at 72°C for 5 min. PCR products were confirmed under UV transillumination and were purified with a gel extraction kit (Qiagen). Purified PCR products were ligated into the pCR2.1 cloning vector (Invitrogen Co., Carlsbad, CA) and then transformed into *E. coli* (Invitrogen Co., Carlsbad, CA) and then transformed into *Escherichia coli* INV-agar. The recombinant *E. coli* strains were cultured in LB medium containing 20% AB-type human serum (Atlanta Biological, Lawrenceville, GA). All mosquitoes were starved for 24 h before artificial blood feeding. To accommodate egg laying, the blood-fed mosquitoes were transferred to Paraffilm-covered glass feeders filled with distilled water and equilibrated at 23°C±2°C and 85%±2% relative humidity. Mosquitoes were fed on 10% sucrose solution containing 0.01% thimerosal, 0.5% NP-40, and 0.002% phenol red dissolved in 0.01 M PBS, pH 7.4, and the contents were homogenized using a pestle (Eppendorf Co., Hamburg, Germany). A two-site homologous sandwich ELISA with circum-sporozoite protein (CSP) monoclonal antibody was performed to confirm sporozoite development in mosquitoes, as described by Lee et al. (11).

**Oral and parenteral immunization.** rPvs25 was dialyzed in 0.01 M PBS and then adjusted to a final concentration of 200 µg in 250 µl of PBS, with or without 10 µg of cholera toxin B subunit (CTB) (1, 19). BALB/c mice were deprived of food and water for 24 h and then orally immunized with 250 µl of PBS containing the proper amounts of antigens. Serum was collected from the eye before the first immunization, as a control, and once each month thereafter to measure the level of antibodies against rPvs25. Three immunizations were given, one each at weeks 0, 1, and 3. Parenteral immunization was also performed, using rPvs25 doses similar to those used for the oral immunization, with the exception of the incomplete adjuvant (23).
transmission-blocking effect of Pvs25 MAb in A. sinensis

Antibody isotyping. To analyze the isotypes of the monoclonal antibody and the sera from immunized mice, a Beadlyte mouse immunoglobulin isotyping kit (Upstate Co., Temecula, CA) was used. Purified MAb was diluted with Beadlyte mouse isotyping serum diluent (Upstate) at 1:25,000 (vol/vol), and the amount of each antibody (IgG1, IgG2a, IgG2b, IgG3, IgM, IgE, and IgA) was determined according to the manufacturer’s instructions. Mean fluorescence intensity (MFI) was measured with a Luminex 100 instrument (Upstate) (9). To assess the sera of immunized mice, the levels of IgG1, IgG2a, IgG2b, IgG3, and IgA antibodies were determined by ELISA, and the absorbance was measured at 490 nm.

Nucleotide sequence accession number. The sequence of Pvs25 from the Korean isolate was deposited in GenBank under accession no. GU256271.1.

RESULTS

Amino acid sequence variation in Pvs25. To determine the complete gene sequence encoding the ookinete surface protein Pvs25, an approximately 600-bp genomic DNA fragment from a Korean isolate was amplified by PCR, using a Pvs25-specific primer set. The PCR products were ligated into a pCR2.1 cloning vector (3.9 kb) and transformed into E. coli INVaF’. The plasmid containing the PCR product (pPvs25) was used for DNA sequence analysis. The cloned Pvs25 gene was 660 bp long and encoded a 219-amino-acid protein with a signal sequence at the N terminus, four tandem EGF-like domains, and a C-terminal putative GPI attachment sequence (GenBank accession no. GU256271.1) (8). Three amino acid polymorphisms were identified between the Korean strain and the SalI strain (GenBank accession no. AF083502). Amino acid (aa) 97 (E in the SalI strain and Q in the Korean strain) and aa 130 (I→T) differed between the two strains, but aa 131 (Q) was the same in both. The amino acid sequence of the Korean isolate was similar to those of Thai isolates (17). In contrast, the amino acid sequence was totally different from those of P. falciparum (GenBank accession no. X07802) and Plasmodium ovale (GenBank accession no. AB051631) (data not shown).

Recombinant protein expression and monoclonal antibody production. rPvs25 was expressed in E. coli strain M15. Protein expression was induced with 0.5 M IPTG, and recombinant protein was purified by Ni-nitrilotriacetic acid chromatography. The protein had a molecular mass of 25 kDa, as determined by SDS-PAGE analysis (Fig. 1A). A monoclonal antibody (Pvs25 MAb) specific to rPvs25 was produced using Sp2/O myeloma cells and BALB/c mice. The Pvs25 MAb was purified from the ascites fluid of immunized mice by protein G Sepharose 4 Fast Flow chromatography. A specific immune response between rPvs25 and the Pvs25 MAb was confirmed by Western blot analysis (Fig. 1B). The monoclonal antibody consisted mainly of IgG2b (Fig. 1C). Additionally, sera of 10 of 16 P. vivax-infected patients were found to react with the purified recombinant antigen (Fig. 2).

Pvs25 MAb-blocked sporozoite development in Anopheles sinensis. In the control group (n = 100), in which mosquitoes were fed by a glass apparatus with patient blood only, 34 A. sinensis mosquitoes tested positive for sporozoite development both by microscopic examination and by ELISA. In contrast, none of the mosquitoes in the Pvs25 MAb-treated group (n = 80) developed sporozoites in their salivary glands.

IgG persistence after parenteral immunization. To investigate the longevity of IgG levels in immunized mice, sera were collected from each group 2 weeks after the final immunization, and their IgG levels were tested against rPvs25 by use of ELISA. The IgG levels of the mice that were immunized parenterally with rPvs25 were higher than those of mice immunized by any of the other antigen delivery methods. In addition, the levels remained high for 6 months. In contrast, no antibodies were produced in mice receiving oral immunizations (Fig. 3A). The IgG2b isotype was dominant in mice immunized with rPvs25 (Fig. 3B).
DISCUSSION

This study shows that a monoclonal antibody against Pvs25 can efficiently block parasite development in the A. sinensis mosquito, which is a malarial vector in the Republic of Korea. Pvs25 is not expressed by P. vivax during its life cycle in humans; therefore, it is not subject to immune selection pressure in the human host. As a consequence, its sequence diversity is low, which simplifies vaccine development (17, 21). The Pvs25 gene is highly conserved between many isolates, but three amino acid substitutions have been identified. One amino acid substitution (E/Q97) is located in the second EGF-like domain, whereas the other two (I/T130 and Q131) are located in the third EGF-like domain (21, 25). The Korean isolate from the present study differs from the salon strain at aa 97 (Q in the Korean isolate and E in the salon strain) and aa 130 (T→I), but the two strains are identical at aa 131 (Q). Interestingly, the North Korean strain (AY639971) has a unique combination of polymorphisms at these amino acid positions, with an E at aa 97, a T at aa 130, and a Q at aa 131. The polymorphic differences in the Pvs25 gene between the North and South Korean strains should be studied further prior to the application of a TBV in the Republic of Korea. Despite the presence of polymorphisms in Pvs25, a salon-based vaccine against the polymorphic target antigen has been found to be effective against field isolates, likely because most of these amino acid substitutions are conservative and, therefore, the tertiary structure and epitopes of the transmission-blocking antibodies are preserved. The low substitution frequencies and bias toward conservative substitutions in Pvs25, combined with the absence of selection due to immune pressure, suggest that antigenic diversity will not limit the efficacy of Pvs25-based TBVs. Therefore, salon-based vaccines should not be affected by Pvs25 polymorphisms in natural isolates of P. vivax and, consequently, should have wide-range applicability (17). Given these theories, a Pvs25-based vaccine developed from the South Korean isolate will likely be effective against the North Korean strain because A. sinensis is also the malarial vector in North Korea.

Although the blocking effect of antisera produced against Pvs25 (Saccharomyces cerevisiae-produced recombinant protein) on oocyst development in Anopheles dirus A has been well studied (8, 17), the transmission-blocking effect of Pvs25 on sporozoite development in A. sinensis has not yet been investigated. Therefore, the efficacy of Pvs25 as the basis for a vaccine to block malaria transmission in South Korea was investigated in this study. rPvs25 was produced in E. coli strain M15. The rPvs25 protein is larger than the Pvs25 protein produced in yeast because it contains the full Pvs25 sequence, including the signal sequence. A monoclonal antibody specific to the recombinant protein was then produced, using Sp2/O myeloma cells and BALB/c mice. A specific immune response between the rPvs25 antigen and the monoclonal antibody (Pvs25 MAb), which consisted mainly of IgG2b (Fig. 1C), was confirmed by Western blot analysis (Fig. 1B). It is possible that hybridoma supernatants would provide clearer results about immunoglobulin isotype than did mouse sera. To test the biological function of the Pvs25 MAb in sporozoite development, A. sinensis mosquitoes were fed patient blood containing gametocytes and the monoclonal antibody. After 16 days, dissected salivary glands were examined for the presence of sporozoites under a microscope, and the results were also determined by an ELISA with a CSP antibody. In the control group (n = 100), comprising A. sinensis mosquitoes fed with patient blood only, 34 A. sinensis mosquitoes showed sporozoite development in both tests. In contrast, none of the mosquitoes in the experimental group (n = 80), treated with the Pvs25 MAb, developed sporozoites in the salivary glands. The low level of infection in the control group prevents us from concluding that the Pvs25 MAb can effectively block sporozoite development in A. sinensis. The low parasitemias in Korean malaria patients make the acquisition of more accurate data very difficult. Future work should aim to increase the numbers of gametocytes in blood samples to overcome this experimental limitation; however, this process will be difficult due to the lack of available P. vivax cultivation methods. In addition, we will modify the transmission blocking assay based on the present study; for example, an isotype control MAb must be used in the control group to exclude a nonspecific reduction of sporozoites, and we will count the number of oocysts in the midguts of parasite-infected mosquitoes in future experiments because it is a direct marker of blocked transmission.

The longevity of antisera produced in response to rPvs25 in BALB/c mice was investigated to evaluate the potential of rPvs25 as a vaccine. The protein was administrated to BALB/c mice both orally and parenterally. Orally immunized mice did not produce antibodies against rPvs25 (Fig. 3A, line b), while parenterally immunized mice did (Fig. 3A, line f). Antibodies
persisted at high levels in the parenterally immunized mice for at least 6 months and consisted primarily of IgG2b (Fig. 3B), as shown in the test of monoclonal antibody production (Fig. 1C). During this experiment, we checked only IgG levels in immunized mice because we obtained small amounts of serum from each mouse; however, in further studies, we will check both IgG levels and the transmission-blocking effect at each time point.

When the frequency of antibodies against rPvs25 in Korean malaria patients (n = 98) with confirmed vivax malaria infections was tested, the positive rate was only 11.22% (n = 11). This result might be due to the fact that Pvs25 is expressed primarily in the midgut of the mosquito after a blood meal. The purpose of a transmission-blocking vaccine is to block zygote formation in the mosquito midgut by use of an antibody that is produced in the host’s bloodstream. In other words, the low antibody frequency in these patients might reflect the active transmission of vivax malaria in South Korea. Given these results, the E. coli-expressed rPvs25 protein could effectively elevate the antibody frequency in the population.

Chemotherapy and vector control have been insufficient to control malaria due to the emergence of both parasite strains resistant to antimalarial drugs and mosquito vectors resistant to insecticides (3, 7, 14, 15). Although TBVs will not prevent the emergence of drug-resistant mutants, these vaccines may prevent their spread. Therefore, the results presented herein are highly encouraging with respect to the applicability of an rPvs25-based vaccine against P. vivax infection in the Republic of Korea.

ACKNOWLEDGMENT

This work was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (03-PJ1-PG1-CH01-0001).

REFERENCES

1. Arakawa, T., D. K. Chong, and W. H. Langridge. 1998. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16:292–297.
2. Barr, P. J., K. M. Green, H. L. Gibson, I. C. Bathurst, I. A. Quakyi, and D. C. Kaslow. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203–1208.
3. Breman, J. G. 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64:1–11.
4. Duffy, P. E., P. Pimenta, and D. C. Kaslow. 1993. Pfs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 177:505–510.
5. Duffy, P. E., P. Pimenta, and D. C. Kaslow. 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 65:1109–1113.
6. Gozar, M. M. G., V. L. Price, and D. C. Kaslow. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:59–64.
7. Harinasuta, T., P. Suntharasamai, and C. Viravan. 1965. Chloroquine-resistant falciparum malaria in Thailand. Lancet ii:657–660.
8. Hiseada, H., A. W. Stowers, T. Tsuboi, W. E. Collins, J. S. Sattabongkot, and N. Suwanabun. 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:6618–6623.
9. Kapturczak, M. H., C. Wasserfall, T. Brusko, M. Campbell-Thompson, T. M. Ellis, M. A. Atkinson, and A. Agarwal. 2004. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am. J. Pathol. 165:1045–1055.
10. Kaslow, D. C., I. A. Quakyi, C. Syin, M. G. Raum, D. B. Keister, and J. E. Coligan. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74–76.
11. Lee, H. W., E. H. Shin, S. H. Cho, H. I. Lee, C. L. Kim, W. G. Lee, S. U. Moon, J. S. Lee, W. J. Lee, and T. S. Kim. 2002. Detection of vivax malaria sporozoites naturally infected in anopheline mosquitoes from endemic areas of northern parts of Gyeonggi-do (Province) in Korea. J. Parasitol. 88:41–44.
12. National Malaria Eradication Service. 1966. Malaria pre-eradication program in Korea. Progress report 1961–1965, p. 44–70. Ministry of Health and Social Affairs, Seoul, Republic of Korea.
13. Paik, Y. H., H. I. Ree, and J. C. Shin. 1988. Malaria in Korea. Jpn. J. Exp. Med. 58:55–66.
14. Rieckmann, K. H., D. R. Davis, and C. D. Hutton. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii:1183–1184.
15. Roberts, D. R., and R. G. Andre. 1994. Insecticide resistance issues in vector borne disease control. Am. J. Trop. Med. Hyg. 50:21–34.
16. Rosenberg, R., and J. Rungsiwongse. 1991. The number of sporozoites produced by individual malaria oocysts. Am. J. Trop. Med. Hyg. 45:574–577.
17. Sattabongkot, J., T. Tsuboi, H. Hiseada, M. Tachihana, N. Suwanabun, T. Rungruang, Y. M. Cao, A. W. Stowers, J. Sirichaisinthop, R. E. Coleman, and M. Torii. 2003. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am. J. Trop. Med. Hyg. 69:536–541.
18. Soh, T. K., T. Lee, K. Y. Im, D. Y. Min, M. H. Ahn, J. J. Kim, and T. S. Yong. 1985. Current status of malaria in Korea. Yonsei Rep. Trop. Med. 16:11–18.
19. Sun, J. B., J. Holmgren, and C. Czerkinsky. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 91:10795–10799.
20. Taylor, D., N. Cloonan, V. Mann, Q. Cheng, and A. Saul. 2000. Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs. Mol. Biol. Parasitol. 110:429–434.
21. Tsuboi, T., D. C. Kaslow, M. M. Gozar, M. Tachihana, Y. M. Cao, and M. Torii. 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Biol. 4:772–782.
22. Tsuboi, T., Y. M. Cao, Y. Hitsumoto, T. Yanagi, and H. Kanbara. 1972. Two antigens of zygotes and ookinetes of Plasmodium yoelii. Acta Trop. 21:235–241.
23. Tsuboi, T., Y. M. Cao, Y. Hitsumoto, T. Yanagi, and H. Kanbara. 1972. Two antigens of zygotes and ookinetes of Plasmodium yoelii. Acta Trop. 21:235–241.
24. Wang, L., L. Kedzierksi, S. L. Wesselingh, and R. L. Coppel. 2003. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. 71:2356–2364.
25. World Health Organization. 1997. World malaria situation in 1994. I. Population at risk. Wkly. Epidemiol. Rec. 72:269–274.
26. Zakeri, S., S. Razavi, and N. D. Djadid. 2009. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Trop. 109:176–180.